AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its ...

AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and ...

The BATURA trial compared the use of Airsupra to albuterol, a commonly used rescue medicine in the US. The trial showed that ...

Remote study conducted at Rutgers and elsewhere finds albuterol-budesonide mix cuts risk for mild cases and may let patients ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations ...

We’re particularly excited by the results of the BATURA Phase IIIb trial exploring AIRSUPRA and its potential to transform rescue treatment in asthma, and look forward to discussing the full ...

Airsupra (albuterol and budesonide) is a brand-name inhaler that doctors may prescribe to treat asthma in adults. It does not have a generic version. Medicare Part D prescription drug plans may ...